Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

A Molecular Hinge Allows Transport Proteins to Move Neurotransmitters Across Brain Cell Membranes

By BiotechDaily International staff writers
Posted on 13 May 2013
Image: Senior author Dr. Shimon Schuldiner (Photo courtesy of the Hebrew University of Jerusalem).
Image: Senior author Dr. Shimon Schuldiner (Photo courtesy of the Hebrew University of Jerusalem).
An international team of molecular biologists has developed a model that shows how components of a protein transport complex act as a molecular hinge to move neurotransmitters across brain cell membranes.

Investigators at the Hebrew University of Jerusalem (Israel) and the Max Planck Institute of Biophysics (Frankfurt am Main, Germany) focused on vesicular monoamine transporter 2 (VMAT2), a member of the largest superfamily of transporters, which is known to convey a variety of neurotransmitters such as adrenaline, dopamine, and serotonin as well as MPP, a neurotoxin linked to Parkinson’s disease.

In the April 9, 2013, issue of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) they described the importance of two anchor points positioned between two six-transmembrane-helix bundles. These two domains provide hinge points about which the two halves of the protein flex and straighten to open and close the translocation pathway, a process that enables alternating exposure of the substrate-binding site. Polar residues that create a hydrogen bond cluster form one of the anchor points of VMAT2, while the other results from hydrophobic interactions.

The investigators, led by Dr. Shimon Schuldiner, professor of biochemistry at the Hebrew University of Jerusalem, said that, "They hope that this knowledge may, in the future, help in designing drugs for treating pathologies involving transporters similar to VMAT, including infectious and neurological diseases."

Related Links:
Hebrew University of Jerusalem
Max Planck Institute of Biophysics



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: The European Commission has approved the use of Avastin combined with chemotherapy as a treatment for women with recurrent ovarian cancer (Photo courtesy of Genentech).

Drug for Treatment of Platinum Resistant Recurrent Ovarian Cancer Approved for Use in Europe

For the first time in more than 15 years the European Commission (EC) has approved a new therapeutic option for the most difficult to treat form of ovarian cancer. Ovarian cancer causes more deaths... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Lab Technologies

view channel
Image: The DrySyn MULTI converts any standard hotplate stirrer into a high performance reaction block (Photo courtesy of Asynt).

New Reaction Vessel Heating System Is Cleaner and Safer

Biotech and other life science researchers can create a safer, cleaner, and more efficient working environment in their laboratories by switching from oil bath-based heating of reaction vessels to a new... Read more

Business

view channel

Global Computational Biology Sector Expected to Reach over USD 4 Billion by 2020

The global market for computational biology is expected to reach USD 4.285 billion by 2020 growing at a compound annual growth rate (CAGR) of 21.1%, according to new market research. Steady surge in the usage and application of computational biology for bioinformatics R&D programs designed for sequencing genomes... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.